Immunotherapy plus chemoradiation for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests two immunotherapy medicines (iparomlimab and tuvonralimab) combined with radiation and standard chemotherapy for advanced head and neck cancer that cannot be removed with surgery. The goal is to see if adding these medicines helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have squamous cell carcinoma of the head and neck (a common type of head and neck cancer) that is locally advanced and cannot be removed with surgery. The main tumor or a neck lymph node must be larger than 5 cm.
- You must not have had any previous cancer treatment for this condition.
- You must be in reasonably good physical condition (able to do light activities) and have a life expectancy of at least 3 months.
- You must have adequate organ function (kidneys, liver, blood counts) as determined by blood tests.
- You must be willing to give written consent and follow the treatment and follow-up schedule.
- You must not have serious heart problems, autoimmune diseases, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with low-dose radiation and chemotherapy for advanced head and neck cancer. It aims to see if this approach can help patients who have not had prior treatment for their cancer.
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.